Durvalumab concentrate for infusion | China Drugs List

Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.

Others

Brand
Imfinzi
Company
AstraZeneca AB (EU authorization holder)
Medicine type
Biologic
Therapeutic area
Oncology
Indications recorded in the public source
Selected EU indications: Used alone in adults with unresectable, locally advanced non-small cell lung cancer expressing PD-L1 on at least 1% of tumor cells, without progression after platinum-based chemoradiotherapy. Also used with gemcitabine and cisplatin as initial treatment for unresectable or metastatic biliary tract cancer. This summary does not establish the approved indications in China.
Indication source and scope
Web page accessed 2026-11-02. Selected overseas indications; does not establish the Chinese approved scope.
Prescribing-information limitations
Regulatory product information / approval evidence is linked; a complete current prescribing-information document has not been verified in this review.
China availability status
Chinese approval, current Chinese indications and continuous market availability were not independently verified in this English-source review.
Overseas status
See the linked overseas regulator / manufacturer evidence. Approval and indications are jurisdiction-specific; current supply is not established.
Insurance classification
Not yet verified
Insurance edition
Chinese national insurance review pending
Insurance verification notes
No reimbursement determination was made for this addition; missing information is not proof of exclusion.

Sources

Evidence reviewed:

Open the interactive record, public price references and discussions